Cabaletta Bio (CABA) News Today → He called Apple at $1.49 and now he says: “Buy these 6 AI stocks.” (From InvestorPlace) (Ad) Free CABA Stock Alerts $12.35 -0.27 (-2.14%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 3:30 AM | americanbankingnews.comEquities Analysts Set Expectations for Cabaletta Bio, Inc.'s FY2028 Earnings (NASDAQ:CABA)May 18 at 4:52 AM | americanbankingnews.comCabaletta Bio (NASDAQ:CABA) Stock Rating Reaffirmed by HC WainwrightMay 17 at 10:44 AM | marketbeat.comFY2028 Earnings Forecast for Cabaletta Bio, Inc. Issued By HC Wainwright (NASDAQ:CABA)Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) - Research analysts at HC Wainwright boosted their FY2028 earnings per share estimates for Cabaletta Bio in a research note issued to investors on Thursday, May 16th. HC Wainwright analyst D. Tsao now expects that the company will post earnings perMay 16 at 8:30 AM | marketbeat.comCabaletta Bio (NASDAQ:CABA) Given Buy Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $30.00 price target on shares of Cabaletta Bio in a research report on Thursday.May 16 at 1:08 AM | msn.comCabaletta Bio Reports Promising Advances in Autoimmune Disease Trials, Looks to Future InnovationsMay 15, 2024 | markets.businessinsider.comWilliam Blair Reaffirms Their Buy Rating on Cabaletta Bio (CABA)May 15, 2024 | marketbeat.comFirst Turn Management LLC Makes New $3.98 Million Investment in Cabaletta Bio, Inc. (NASDAQ:CABA)First Turn Management LLC purchased a new stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 175,359 shares of the company's stock, vMay 15, 2024 | marketbeat.comCabaletta Bio (NASDAQ:CABA) Shares Gap Up to $11.23Cabaletta Bio (NASDAQ:CABA) Shares Gap Up to $11.23May 15, 2024 | investorplace.comCABA Stock Earnings: Cabaletta Bio Misses EPS for Q1 2024May 15, 2024 | finance.yahoo.comCabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 15, 2024 | globenewswire.comCabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 15, 2024 | msn.comCabaletta Bio to Present at H.C. Wainwright BioConnect Investor ConferenceMay 14, 2024 | marketbeat.comVictory Capital Management Inc. Acquires 337,277 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA)Victory Capital Management Inc. grew its holdings in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 506.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 403,927 shares of the company's stock afMay 13, 2024 | globenewswire.comCabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQMay 13, 2024 | americanbankingnews.comCabaletta Bio, Inc. (NASDAQ:CABA) Given Average Rating of "Buy" by AnalystsMay 10, 2024 | marketbeat.comCabaletta Bio (NASDAQ:CABA) Shares Down 7.9% Cabaletta Bio (NASDAQ:CABA) Shares Down 7.9%May 10, 2024 | msn.comRetinopathy With Long-Term HCQ Use: Large Study IDs Risk FactorsMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cabaletta Bio as CABA-201 Enters RESET Trial with Promising Therapeutic PotentialMay 1, 2024 | marketbeat.comCabaletta Bio (NASDAQ:CABA) Trading Up 8.9%Cabaletta Bio (NASDAQ:CABA) Stock Price Up 8.9%April 29, 2024 | marketbeat.comCabaletta Bio (NASDAQ:CABA) Sees Unusually-High Trading VolumeCabaletta Bio (NASDAQ:CABA) Sees Strong Trading VolumeApril 29, 2024 | marketbeat.comCabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Up 16.1% in AprilCabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 9,870,000 shares, a growth of 16.1% from the March 31st total of 8,500,000 shares. Based on an average daily trading volume, of 954,800 shares, the short-interest ratio is currently 10.3 days.April 27, 2024 | investing.comCabaletta Bio Inc (CABA)April 25, 2024 | marketbeat.comCabaletta Bio (NASDAQ:CABA) Stock Price Down 8.7%Cabaletta Bio (NASDAQ:CABA) Stock Price Down 8.7%April 25, 2024 | marketbeat.comJennison Associates LLC Buys 204,261 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA)Jennison Associates LLC lifted its stake in Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 14.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,626,628 shares of the company's stock after acApril 18, 2024 | msn.comPhilly-area biotech is worried about Congress’ crackdown on Chinese manufacturersApril 17, 2024 | marketbeat.comCabaletta Bio (NASDAQ:CABA) Stock Price Down 4.2%Cabaletta Bio (NASDAQ:CABA) Shares Down 4.2%April 17, 2024 | msn.com🛠️ One Philly rowhouse at a time | Morning NewsletterApril 13, 2024 | marketbeat.comCabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Up 19.9% in MarchCabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 8,500,000 shares, an increase of 19.9% from the March 15th total of 7,090,000 shares. Based on an average daily volume of 946,600 shares, the days-to-cover ratio is currently 9.0 days.April 12, 2024 | marketbeat.comCabaletta Bio, Inc. (NASDAQ:CABA) Shares Bought by Vanguard Group Inc.Vanguard Group Inc. lifted its holdings in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 14.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,968,108 shares of the company's stock after acquiring an additional 246,April 5, 2024 | marketbeat.comCabaletta Bio (NASDAQ:CABA) Stock Price Up 5% Following Analyst UpgradeCabaletta Bio (NASDAQ:CABA) Trading 5% Higher After Analyst UpgradeApril 5, 2024 | marketbeat.comCabaletta Bio's (CABA) Overweight Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating and issued a $50.00 price objective on shares of Cabaletta Bio in a report on Friday.April 4, 2024 | marketbeat.comCabaletta Bio (NASDAQ:CABA) Given New $30.00 Price Target at CitigroupCitigroup raised their target price on shares of Cabaletta Bio from $26.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday.March 27, 2024 | marketbeat.comWellington Management Group LLP Makes New Investment in Cabaletta Bio, Inc. (NASDAQ:CABA)Wellington Management Group LLP bought a new position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 246,570 shares of the company's stMarch 23, 2024 | investing.comStifel lifts Cabaletta Bio target to $32 on myositis positionMarch 23, 2024 | finance.yahoo.comCabaletta Bio Inc (CABA) Earnings: Aligns with EPS Projections, Forecasts Extended Cash RunwayMarch 22, 2024 | markets.businessinsider.comStrong Buy on Cabaletta Bio: Promising CAR T Candidate and Robust Financial OutlookMarch 22, 2024 | marketbeat.comCabaletta Bio's (CABA) "Overweight" Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating and set a $50.00 target price on shares of Cabaletta Bio in a research report on Friday.March 21, 2024 | markets.businessinsider.comCabaletta Bio Earns ‘Buy’ Rating on Impressive Clinical Progress and Strategic Market PositioningMarch 21, 2024 | investorplace.comCABA Stock Earnings: Cabaletta Bio Misses EPS for Q4 2023March 21, 2024 | msn.comCabaletta gets FDA orphan drug status for systemic sclerosis drugMarch 21, 2024 | finance.yahoo.comCabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 21, 2024 | globenewswire.comCabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 20, 2024 | markets.businessinsider.comCabaletta Bio Says FDA Grants Orphan Drug Designation To CABA-201 To Treat Systemic SclerosisMarch 20, 2024 | finance.yahoo.comCabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic SclerosisMarch 19, 2024 | marketbeat.comCabaletta Bio Target of Unusually Large Options Trading (NASDAQ:CABA)Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) was the target of unusually large options trading on Tuesday. Investors acquired 10,680 put options on the company. This represents an increase of 974% compared to the typical daily volume of 994 put options.March 19, 2024 | msn.comA major cog in Philly biotech is in congressional crosshairs for its Chinese ownershipMarch 18, 2024 | marketbeat.comCabaletta Bio (NASDAQ:CABA) Shares Down 6.4% Cabaletta Bio (NASDAQ:CABA) Stock Price Down 6.4%March 13, 2024 | marketbeat.comCabaletta Bio (CABA) to Release Quarterly Earnings on ThursdayCabaletta Bio (NASDAQ:CABA) will be releasing earnings on Thursday, March 14, Yahoo Finance reports.March 11, 2024 | marketbeat.comCabaletta Bio (NASDAQ:CABA) Trading Down 4.5%Cabaletta Bio (NASDAQ:CABA) Stock Price Down 4.5%March 5, 2024 | msn.comCabaletta Bio Set to Ignite Conversation at Upcoming Health Care Conferences Get Cabaletta Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter. Email Address POTUS in ‘25 Not Biden/Trump, But (Ad)And I believe when they do take the oath of office, their fingers will be crossed… and America will descend into chaos. Click here now to see my urgent election warning. CABA Media Mentions By Week CABA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CABA News Sentiment▼0.370.42▲Average Medical News Sentiment CABA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CABA Articles This Week▼203▲CABA Articles Average Week Get Cabaletta Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: EXAI News Today KYTX News Today HUMA News Today NVAX News Today PRME News Today VALN News Today PROK News Today ALEC News Today HLVX News Today ALLO News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CABA) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryShocking $16T Elon Musk Crypto LeakCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceMost important medical advance in 100 yearsThe Oxford ClubCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMissed NVDA? Buy this AI stock NOWChaikin AnalyticsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
